Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

NCT05191706 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05191706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05191706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
January 4, 2022
Completion date
August 22, 2025
Enrollment
17 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cataract